Post by Gubra

This week, at Gubra’s Annual General Meeting, we marked the close of an excellent year for Gubra. Highlights include our landmark outlicensing deal with AbbVie on the obesity-agent ABBV-295 (Amylin), the advancement of BI-3034701 (triple agonist) also for the treatment of obesity into mid-clinical stage development, and the progress of GUB-UCN2, our lead asset for high-quality weight loss, expected to enter clinical trials during the first half of 2026. In 2025, Gubra delivered a record operating profit of DKK 2.2 billion. 10% will be invested in Gubra Green reaffirming our commitment to advancing human and planetary health. For more, read Gubra’s 2025 Annual Results here: https://lnkd.in/ej9bhjWe These outstanding results reflect the passion, collaboration, and brilliance of our colleagues across Gubra. Thank you for making this possible. And to our shareholders, thank you for your trust and continued support of Gubra’s long-term vision. #Gubra #AGM #Sustainability #GubraGreen #Innovation #LongTermValue